Hospira (HSP) Q4 2011 Earnings Call February 14, 2012 9:00 am ET Executives Karen King - Thomas E. Werner - Chief Financial Officer and Senior Vice President of Finance Sumant Ramachandra - Chief Scientific Officer and Senior Vice President of Research & Development & Medical Affairs Analysts Gregory B. Gilbert - BofA Merrill Lynch, Research Division Ami Fadia - UBS Investment Bank, Research Division Louise A. Chen - Collins Stewart LLC, Research Division Marshall Urist - Morgan Stanley, Research Division David H. Roman - Goldman Sachs Group Inc., Research Division Christopher Schott - JP Morgan Chase & Co, Research Division Matthew Taylor - Barclays Capital, Research Division PresentationOperator
Welcome to Hospira's Fourth Quarter and Full Year 2011 Conference Call. [Operator Instructions] I will now turn the call over to Karen King, Vice President of Investor Relations. Karen, you may now begin your conference. Karen King Thank you. Good morning, everyone, and welcome to our conference call and webcast regarding Hospira's financial results for the fourth quarter and full year 2011, as well as our projections for 2012. Participating in today's call are Mike Ball, Chief Executive Officer of Hospira; Tom Werner, Senior Vice President of Finance and Chief Financial Officer; and Sumant Ramachandra, Senior Vice President and Chief Scientific Officer. We will be making some forward-looking statements today which are subject to risks and uncertainties and other factors that may cause actual results to differ materially from those indicated. A discussion of these factors is included in the risk factors and MD&A sections in Hospira's latest annual report on Form 10-K and subsequent Form 10-Qs on file with the SEC. We undertake no obligation to release publicly any revisions the forward-looking statements as a result of subsequent events or developments.